Drug Trial Radar · NCT07699328
A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
315
Planned (sponsor's estimate)
Start
Mar 26, 2024
Primary completion
Jan 1, 2029
Study completion Oct 1, 2029
Sponsor
- Lead sponsor
- Voronoi, IncIndustry
- Sponsor type
- Industry
- First posted
- Jul 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This first-in-human, Phase 1/2, multicenter, open-label, non-randomized study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of VRN110755, a highly selective oral epidermal growth factor receptor (EGFR) inhibitor, in patients with EGFR-mutant non-small cell lung cancer (NSCLC). The study includes a Phase 1a dose-escalation portion, a Phase 1b dose-expansion portion, and a Phase 2 evaluation. The study is designed to determine the maximum tolerated dose and recommended Phase 2 dose of VRN110755 and to evaluate preliminary and confirmatory antitumor activity in patients with EGFR-mutant NSCLC, including patients with acquired resistance following EGFR tyrosine kinase inhibitor therapy.
Conditions
- EGFR-Mutant Non-Small Cell Lung Cancer
Interventions
VRN110755Drug
VRN110755 is an investigational highly selective oral EGFR inhibitor supplied as capsules for oral administration. The drug is designed to target activating EGFR mutations and selected resistance mutations, including C797S, in patients with EGFR-mutant NSCLC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Estimate of Maximum Tolerated Dose (MTD) of VRN110755Time frame: 28 days
- Number of participants with dose-limiting toxicities (DLTs) following treatment with VRN110755Time frame: 28 days
- Number of participants experiencing treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events leading to discontinuationTime frame: From first dose until end of study (up to approximately 6 years)
- Number of participants with changes in vital signs from baseline following treatment with VRN110755Time frame: From baseline through End of Treatment (up to approximately 6 years)
- Number of participants with changes in laboratory test results from baseline following treatment with VRN110755Time frame: From baseline through End of Treatment (up to approximately 6 years)
- Number of participants with changes in physical examination findings from baseline following treatment with VRN110755Time frame: From baseline through End of Treatment (up to approximately 6 years)
- Number of participants with changes in ophthalmologic examination findings from baseline following treatment with VRN110755Time frame: From baseline through End of Treatment (up to approximately 6 years)
- Number of participants with changes in electrocardiogram (ECG) parameters from baseline following treatment with VRN110755Time frame: From baseline through End of Treatment (up to approximately 6 years)
- Number of participants with changes in Eastern Cooperative Oncology Group (ECOG) Performance Status from baseline following treatment with VRN110755Time frame: From baseline through End of Treatment (up to approximately 6 years)
Locations
29 sites in 10 countries. Site status is shown where the registry gives one.
Southern Oncology Clinical Research Unit
Bedford Park, South Australia, Australia · Recruiting
Monash Medical Centre Clayton
Clayton, Victoria, Australia · Recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
AP-HM Hôpital Nord
Marseille, Bouches-du-Rhône, France · Recruiting
Centre Georges François Leclerc
Dijon, Côte-d'Or, France · Recruiting
Prince of Wales Hospital
Hong Kong, Hong Kong · Recruiting
Queen Mary Hospital
Hong Kong, Hong Kong · Recruiting
Hospital Kuala Lumpur
Kuala Lumpur, Malaysia · Recruiting
University Malaya Medical Centre
Kuala Lumpur, Malaysia · Recruiting
Institut Kanser Negara
Putrajaya, Malaysia · Recruiting
Hospital Umum Sarawak
Kuching, Sarawak, Malaysia · Recruiting
National Cancer Centre Singapore
Singapore, Singapore · Recruiting
Tan Tock Seng Hospital
Singapore, Singapore · Recruiting
Severance Hospital Yonsei University Health System
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea · Recruiting
The Catholic University of Korea, St. Vincent's Hospital
Suwon, Gyeonggi-do, South Korea · Recruiting
Chungbuk National University Hospital
Cheongju-si, North Chungcheong, South Korea · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Hospital Regional Universitario de Málaga - Hospital Civil
Málaga, Spain · Recruiting
ICO Badalona - Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, Spain · Recruiting
ICO l'Hospitalet - Hospital Duran i Reynals
L'Hospitalet de Llobregat, Barcelona, Spain · Recruiting
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan · Recruiting
Taichung Veterans General Hospital
Taichung, Taiwan · Recruiting
National Taiwan University Hospital
Taipei, Taiwan · Recruiting
Taipei Medical University Hospital
Taipei, Taiwan · Recruiting
Taipei Veterans General Hospital
Taipei, Taiwan · Recruiting
Phramongkutklao Hospital
Thung Phaya Thai, Bangkok Metropolis, Thailand · Recruiting
Songklanagarind Hospital Prince of Songkla University
Hat Yai, Changwat Songkhla, Thailand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.